Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alcyone Lifesciences

Request full access

Pioneers next-generation intra-CSF CNS precision gene-based therapeutics for complex neurological conditions

Ayer, United StatesFounded 2010Biotech & Life Sciences

About Alcyone Lifesciences

Alcyone Therapeutics is a biotechnology company focused on developing next-generation genetic therapies for severe neurological disorders. The company leverages its expertise in genetic therapy research, cerebrospinal fluid (CSF) biofluid dynamics, bioengineering, and chemistry, manufacturing, and controls (CMC) to create transformative treatments. Alcyone's core innovation lies in its precision intra CSF dosing and delivery system, which aims to improve the efficacy of treatments for complex neurological conditions. The company operates in the biotechnology market, primarily serving patients with severe neurological disorders. Alcyone's business model involves collaborating with research institutions, such as The Abigail Wexner Research Institute at Nationwide Hospital, to develop and commercialize its gene-based therapeutics. Revenue is generated through partnerships, grants, and potentially future sales of approved therapies.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
9
Open positions
None listed
Dealroom signal
60.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Genetics and genomics, Spinout, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2C

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Sep 2025 $85M — Biogen ↗
LATE VC✓Equity / VC Apr 2025 $0 — Nationwide Children's Hospital ↗
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Alcyone Lifesciences website traffic

Latest recorded traffic for Alcyone Lifesciences is 20 monthly website visits, down 98.8% over the last three months. Alcyone Lifesciences's team declined 60.9% over the past year.

Latest monthly visits20 3-month web change-98.8% 1-year team growth-60.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alcyone Lifesciences in the Ayer ecosystem

Live from Dealroom

The Alcyone Lifesciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Edgar Jannotta
  • Harbor Light Capital Partners

Series B and later2 investors entered at this stage

  • RTW Investments
  • Nationwide Children's Hospital

Other known investors3 additional known investors

  • Biogen
  • Cornell Tech
  • Cornell University
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Alcyone Lifesciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.